Related Experiment Video
Updated: Jan 10, 2026
Nephrotic Syndrome I : Introduction
Published on: June 19, 2025
Case reports of heart failure after therapy with a tumor necrosis factor antagonist
Hyon J Kwon1, Timothy R Coté, Michael S Cuffe
1Division of Epidemiology, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland 20852, USA. kwon@cber.fda.gov
Background:
Etanercept and infliximab are U.S. Food and Drug Administration-approved tumor necrosis factor (TNF) antagonists.
Objective:
To describe adverse event reports of heart failure after TNF antagonist therapy.
Design:
Case series.
Setting:
The U.S. Food and Drug Administration's MedWatch program.
Patients:
47 patients who developed new or worsening heart failure during TNF antagonist therapy.
Measurements:
Clinical and laboratory reports.
Results:
After TNF antagonist therapy, 38 patients developed new-onset heart failure and 9 patients experienced heart failure exacerbation. Of the 38 patients with new-onset heart failure, 19 (50%) had no identifiable risk factors. Ten patients younger than 50 years of age developed new-onset heart failure after receiving TNF antagonists. After TNF antagonist therapy was discontinued and heart failure therapy was started in these 10 patients, 3 had complete resolution of heart failure, 6 improved, and 1 died.
Conclusion:
In a fraction of patients, TNF antagonists might induce new-onset heart failure or exacerbate existing disease.
More Related Videos
Related Concept Videos
01:30Heart Failure VII: Nursing Interventions
01:22Heart Failure VI: Adjunct Therapies
01:30Heart Failure V: Medical Management
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:27Tumor Immunotherapy